BCR and B-cell chronic lymphocytic leukemia: Gain-of-function mutations have been identified as well in the treatment of CLL using ibrutinib, causing BCR signaling to continue functioning normally despite BTK inhibition, thus highlighting the important role that BCR signaling inhibition has on the effect of BTK inhibition [63].